LCB Issues Interpretive Statement re: Use of Additives in Cannabis Products

Having trouble viewing this email? View it as a Web page.

Left justified header

November 9, 2022

Interpretive Statement: Use of Additives in Authorized Cannabis Products

This interpretive statement addresses the use of cannabidiol (CBD) product and whether other cannabinoids and additives, such as hemp-derived CBG and CBN, may be added to cannabis products or sold as stand-alone products authorized for production, processing, and sale under chapter 69.50 RCW. Below is more complete context and analysis of this topic.

INTERPRETIVE STATEMENT: CBD is the only cannabinoid that can be introduced into the I-502 system from outside the system. CBD originating from outside the I-502 system may be added to cannabis products authorized for sale in the I-502 system. RCW 69.50.326 does not allow any other cannabinoid, including but not limited to hemp-derived CBG and CBN to be added to any authorized cannabis product sold within the I-502 system or sold as a stand-alone product within the I-502 system.

Interpretive Statements are agency-level explanatory documents intended to convey the WSLCB’s interpretation of law and regulation as it existed at the time statement was issued. Current statements are advisory.

Notice of WSLCB Interpretive Statement Number IS 22-01 was filed with the Washington State Code Reviser on November 9, 2022 as WSR 22-23-056.  

Additional information can be found on the WSLCB Policy Statements webpage.